Formycon AG
- BID
18.42
- ASK
18.54
- 280 Units280 Units
- 07/23, 14:23:19 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
34.27%
Market Cap
324.12 Mil.
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-3.66 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 18.42 G | 0 Units |
| PRICE DETERMINATION TIME | 07/23/2026 / 02:16:12 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 18.72 | 18.32 |
| PREV. DAY'S PRICE | 18.34 | (07/22) |
| CHANGE DAY BEFORE | +0.08 | 0.44 % |
| 52 WEEK HIGH / LOW | 31.05 (07/28) | 16.16 (03/23) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | 4.76 | -7.18 | -3.66 | -0.68 | 0.21 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | 11.84 | - | - | - | 88.57 |
PRICE - BOOK RATIO | 1.80 | 2.03 | 1.13 | - | - |
PRICE - SALES RATIO | 11.65 | 13.33 | 10.17 | - | - |
PRICE - CASH FLOW RATIO | - | - | 39.25 | - | - |
Master Data
| WKN | A1EWVY |
| ISIN | DE000A1EWVY8 |
| SYMBOL | FYB |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Formycon AG |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Euro |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 17.67 Mil. |
| MARKET CAPITALISATION | 324.12 Mil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 1.78 % | -6.33 % | -1.40 % | -23.42 % | -34.27 % | -70.94 % | -68.38 % | -28.64 % |
| HIGH | 18.72 | 20.40 | 22.55 | 24.20 | 31.05 | 69.30 | 92.50 | 26.55 |
| LOW | 17.58 | 17.58 | 17.54 | 16.16 | 16.16 | 16.16 | 16.16 | 16.16 |
Dividende
pro Aktie
Formycon AG does not deliver dividend information
Company profile
Formycon AG engages in the manufacture of biosimilar drugs and formulations. Its product candidates include FYB201, FYB202, FYB203, and FYB205, which focuses in the opthalmology and immunology disease areas. The company was founded by Friedrich Wilhelm Steinweg and Nicolas Combé in 2007 and is headquartered in Munich, Germany.
Structured products for Formycon AG
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
(in 20 days)
08/12/26Q2 2026 Earnings Release
(in 53 days)
09/14/26H.C. Wainwright Global Investment Conference
(in 60 days)
09/21/26Berenberg and Goldman Sachs German Corporate Conference
(in 75 days)
10/06/26The Society for Mining, Metallurgy & Exploration Conference
(in 112 days)
11/12/26Q3 2026 Earnings Release